Protective effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against intestinal ischemia-reperfusion injury in the rat.
OBJECTIVE
Ischemia-reperfusion (I-R) injury of the intestine is a significant problem because the initial damage caused by ischemia is exacerbated by reperfusion. In this study, we examined the protective effect of montelukast against I-R-induced intestinal tissue damage.


METHODS
Eight-week-old male Sprague-Dawley rats were randomly divided into three treatment groups : a sham-operated group, a group receiving I-R, and a group receiving I-R plus montelukast (I-R/M). Tissue samples were evaluated and scored histologically. The blood levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and cardiotrophin-1 (CT-1) were measured.


RESULTS
In the I-R group, the histological score and the levels of serum MDA and MPO were increased compared with those in the control group. In the I-R/M group, the histological score and serum MDA and MPO levels were significantly decreased compared with those in the I-R group. Additionally, compared with the IR group, the I-R/M group had increased serum GSH and CT-1 levels and a decreased intestinal injury score. Ileal sections from the I-R/M group showed minimal alterations, characterized by moderate lifting of the epithelial layer from the lamina propria, and few apoptotic enterocytes were observed compare with the number in the I-R group.


CONCLUSIONS
The findings of the present study demonstrated that montelukast can protect I-R-induced intestinal damage in rats.
Department of Emergency Medicine, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey. drarifduran@gmail.com
A
A
Duran
Department of Pediatric Surgery, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
H
H
Otiük
Department of Histology and Embryology, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
E H
EH
Terzi
Department of Medical Biochemistry, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
M
M
Tosun
Department of Pediatric Surgery, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
H
H
Oziiü
Department of Emergency Medicine, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
T
T
Ocak
Department of Medical Biochemistry, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.
A
A
Kiiüer
D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D003521:Cyclopropanes; D016207:Cytokines / Q000097:blood; D005978:Glutathione / Q000097:blood; D007422:Intestines / Q000098:blood supply*; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008643:Mesentery / Q000098:blood supply; D018384:Oxidative Stress / Q000502:physiology; D009195:Peroxidase / Q000097:blood; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018077:Receptors, Leukotriene / Q000187:drug effects; D015427:Reperfusion Injury / Q000517:prevention & control*; D013440:Sulfides
D000085:Acetates; D003521:Cyclopropanes; D016207:Cytokines; D020024:Leukotriene Antagonists; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; D008315:Malondialdehyde; C092073:cardiotrophin 1; D009195:Peroxidase; D005978:Glutathione; C083169:leukotriene D4 receptor; C093875:montelukast